NeoGenomics $230 million stock and $345 million convertible notes offerings
We advised the joint book-running managers on the public offerings of stock and convertible notes
1/11/2021

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by NeoGenomics, Inc. of $345 million aggregate principal amount of its 0.250% convertible senior notes due 2028, which included $45 million aggregate principal amount of notes issued pursuant to the exercise in full of the underwriters’ option to purchase additional notes. In addition, Davis Polk advised counterparties to capped call transactions in connection with the convertible senior notes offering.

Davis Polk also advised the joint book-running managers in connection with NeoGenomics’ concurrent $230 million SEC-registered offering of 4,693,876 shares of its common stock, which included 612,244 shares from the full exercise of the underwriters’ option to purchase additional shares.

Headquartered in Fort Myers, Florida, NeoGenomics operates a network of cancer-focused testing laboratories in the United States as well as in Switzerland and Singapore.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associate Claire A. Bacon. The equity derivatives team included partner Mark M. Mendez and associates Annie Li and Danielle Forni. The tax team included partner Michael Farber and associate Yixuan Long. Partner Frank J. Azzopardi and associate Christopher C. Woller provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.